Replies to post #2785 on Theralase Technologies Inc (TLTFF)

[Geo2014]

In a nutshell, same type of therapy but different compound and current indication (prostate).

[-3]

I am a layman with a keen interest from an investment perspective . TLT targets the mechanics of mammal cell death " apoptosis " or normal cell death .

The Tookad Solution shuts off blood supply and starves the cell to death . Seems like another cleaver approach to the same problem . Maybe not as clean or elegant as TLT's approach .

TLT uses a compound common to the body as principal carrier Inferin ( iron ) . The cancer cell has 16 x more receptors for it than a normal cell . Cancer is an iron hog . Part of the reason for no damage to adjacent cells is that a normal cell uses less and it kicks out what it doesn't use quickly .

They piggyback another metalic compound in the solution , who's deadly purpose is hidden , that when activated by light releases a singlet of oxygen which is the message to any cell for the DNA to divide . By dividing the cell dies .

This is of coarse a superficial explanation but a start for your inquiry .